Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Deffered Revenue (2011 - 2013)

Catalyst Pharmaceuticals posted quarterly Non-Current Deffered Revenue of $19131.0 for Q4 2013, down 12.56% year-on-year from $21878.0 in Q4 2012, and down 4.54% on a QoQ basis from $20040.0 in Q3 2013.

Catalyst Pharmaceuticals (CPRX) has 3 years of Non-Current Deffered Revenue data on file, last reported at $19131.0 in Q4 2013.

  • For the quarter ending Q4 2013, Non-Current Deffered Revenue fell 12.56% year-over-year to $19131.0; the trailing twelve-month figure through Dec 2013 stood at $19131.0 (down 12.56% YoY), and the FY2013 full-year result was $19131.0, down 12.56% from the prior year.
  • Non-Current Deffered Revenue for Q4 2013 stood at $19131.0, down from $20040.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $22004.0 in Q2 2012 and bottomed at $9518.0 in Q4 2011.
  • The 3-year median for Non-Current Deffered Revenue is $20653.0 (2013), against an average of $19212.7.
  • The widest annual swing landed in 2012, when Non-Current Deffered Revenue jumped 129.86%; it then slipped 12.56% in 2013.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $9518.0 in 2011, then surged by 129.86% to $21878.0 in 2012, then fell by 12.56% to $19131.0 in 2013.
  • The last three Non-Current Deffered Revenue figures came in at $19131.0 (Q4 2013), $20040.0 (Q3 2013), and $20653.0 (Q2 2013), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 225.10 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Catalyst Pharmaceuticals 3.82 Bn 3.07 Bn 134.92 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 19,131.00
Sep 30, 2013 20,040.00
Jun 30, 2013 20,653.00
Mar 31, 2013 21,265.00
Dec 31, 2012 21,878.00
Jun 30, 2012 22,004.00
Dec 31, 2011 9,518.00